Initiation of New Glucose-Lowering Therapies May Act to Reduce Physical Activity Levels: Pooled Analysis From Three Randomized Trials

Thomas Yates*, Jack A. Sargeant, James A. King, Joe Henson, Charlotte L. Edwardson, Emma Redman, Gaurav S. Gulsin, Emer M. Brady, Ehtasham Ahmad, David J. Stensel, David R. Webb, Gerry P. McCann, Kamlesh Khunti, Melanie J. Davies

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

OBJECTIVE Sodium–glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) reduce body weight and improve cardiometabolic health, but their effect on physical activity is unknown. RESEARCH DESIGN AND METHODS We pooled data (n = 148) from three randomized trials to investigate the effect of empagliflozin (SGLT2i) and liraglutide (GLP-1RA), in comparison with sitagliptin (dipeptidyl peptidase 4 inhibitor) and dietary therapies, on accelerometer-assessed physical activity. RESULTS Liraglutide (mean 21,144 steps/day; 95% CI 22,069 to 2220), empagliflozin (21,132 steps/day; 21,739, 2524), and sitagliptin (2852 steps/day; 21,625, 278) resulted in reduced total daily physical activity after 6 months (P < 0.01 vs. control). Moderate-to vigorous-intensity physical activity was also reduced. Dietary interventions led to no change or an increase in physical activity. CONCLUSIONS The initiation of all glucose-lowering therapies was associated with reduced physical activity, warranting further investigation.

Original languageEnglish
Pages (from-to)2749-2752
Number of pages4
JournalDiabetes care
Volume45
Issue number11
DOIs
Publication statusPublished - 2022 Nov

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialised Nursing

Fingerprint

Dive into the research topics of 'Initiation of New Glucose-Lowering Therapies May Act to Reduce Physical Activity Levels: Pooled Analysis From Three Randomized Trials'. Together they form a unique fingerprint.

Cite this